We’re honored to have Alexandra Pichard Nielsen, Vice President for Business Development at Porton Pharma Solutions Ltd., join us at BOS Basel 2023!
We are excited to witness Alexandra’s expertise and leadership in action as she explores new opportunities, fosters …
NEW YORK, NY – On March 20th through March 23rd, 2023, Midtown New York City was home to the 95th Annual DCAT Week, one of the world’s largest and highly recognized and attended business events for the pharmaceutical industry. During …
Porton’s recognition by Roche is a testament to the high-quality service and technical expertise that comes with working with a leading global end-to-end CDMO.
Shanghai China (December 16, 2022) – Porton Pharma Solutions (hereinafter referred to as Porton) was recently …
The year 2022 is an important milestone for Porton. Despite of the uncertainties of the external environment, we always keep in mind Porton’s mission of “Enabling public’s early access to good medicines” to overcome those challenges and ensure delivery through …
J-STAR Research is pleased to announce our collaboration in the 3rd Edition of Fundamentals of Solid Formulation (FSF2022) webinar series, featuring an impressive line-up of speakers and topics.
This is a 4-week webinar series with a webinar every Wednesday from …
March 1st, 2022, Chongqing · China – Porton Pharma Solutions Ltd. announced an investment of 420 million to expand CDMO Production Capacity of Small Molecule API in Porton Pharma (Jiangxi) Co., Ltd. which is mainly engaged in customized production of …
Chongqing China, February 10, 2022–Porton Pharma Solutions Ltd. (Porton) today announced it will expand its API CDMO production capacity with approximately RMB 260 million investment in Changshou site, Chongqing in order to capture growing market demand from our global pharmaceutical …
Chongqing · China: On January 16, 2022, Porton Pharma Solutions Ltd. released the “2021 Annual Performance Forecast”. The company expects that revenue and net profit will continue to maintain strongly growth in the year of 2021.
2021 Annual Performance Forecast…
Subtitle: Enabling Public’s Early Access to Good Medicines
On November 6, 2021, Porton Pharma Solutions Ltd. (hereinafter referred to as Porton, stock code: 300363) and Honeywell (NASDAQ code: HON) held a Signing Ceremony of Strategic Cooperation Agreement at the 4th …
Chongqing, China，August 18, 2021-Porton Pharma Solutions Ltd. (Porton) today announced that it is to acquire 70% of equity of Hubei Yuyang Pharmaceutical Co., Ltd. (Yuyang) with the dealing price of RMB 171.5 million. The acquisition will enhance Porton’s existing capabilities …
On Saturday, June 6, Porton and Tianjin University National Engineering Research Center of Industrial Crystallization Technology (CICT) announced a school-enterprise strategic cooperation to jointly advance CICT’s resource investment, technology development, talent training, teaching, research, industry-university cooperation, and innovation.
The first …